Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity
M. Wantoch, E. B. Wilson, A. P. Droop, S. L. Phillips, M. Coffey, Y. M. El-Sherbiny, T. D. Holmes, A. A. Melcher, L. F. Wetherill, G. P. Cook
This study shows reovirus treatment affects CD56dim and CD56bright NK cell subsets differently, modulating their activity and signaling pathways in vivo.
bioRxiv · Dec 16, 2020 · PreprintImmunology